Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OBSERVATIONAL STUDY OF EFFECTIVENESS AND SAFETY OF THE FIRST LINE NIVOLUMAB PLUS IPILIMUMAB WITH OR WITHOUT CHEMOTHERAPY FOR ADVANCED / RECURRENT NON-SMALL CELL LUNG CANCER IN JAPAN (LIGHT-NING)

Next Previous
X
Search
Trial Profile

AN OBSERVATIONAL STUDY OF EFFECTIVENESS AND SAFETY OF THE FIRST LINE NIVOLUMAB PLUS IPILIMUMAB WITH OR WITHOUT CHEMOTHERAPY FOR ADVANCED / RECURRENT NON-SMALL CELL LUNG CANCER IN JAPAN (LIGHT-NING)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Antineoplastics; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LIGHT-NING
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 05 Dec 2023 Status changed from recruiting to completed.
    • 02 Jul 2021 Status changed from not yet recruiting to recruiting.
    • 04 Jun 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top